

US011559437B2

(12) United States Patent

Steward et al.

(54) MULTI-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE

(71) Applicant: Smith & Nephew PLC, Watford (GB)

(72) Inventors: Daniel Lee Steward, Hull (GB); Emma Cole, Hull (GB); Hannah Bailey Sidebottom, Lincoln (GB); Neil Patrick, Hull (GB)

Assignee: Smith & Nephew PLC, Watford (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 848 days.

(21) Appl. No.: 16/345,196

(22) PCT Filed: Oct. 24, 2017

(86) PCT No.: PCT/EP2017/077154

§ 371 (c)(1),

(2) Date: **Apr. 25, 2019**

(87) PCT Pub. No.: **WO2018/077872**

PCT Pub. Date: **May 3, 2018**

(65) Prior Publication Data

US 2019/0274889 A1 Sep. 12, 2019

(30) Foreign Application Priority Data

(51) Int. Cl. A61F 13/00

A61F 13/02

(2006.01) (2006.01)

(Continued)

(10) Patent No.: US 11,559,437 B2

(45) **Date of Patent:**

Jan. 24, 2023

(52) U.S. Cl.

CPC .. A61F 13/00029 (2013.01); A61F 13/00038 (2013.01); A61F 13/00068 (2013.01); A61F 13/0226 (2013.01); A61F 13/0286 (2013.01); A61M 1/90 (2021.05); A61F 2013/00097 (2013.01); A61F 2013/00548 (2013.01);

(Continued)

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

730,062 A 6/1903 Widmer 1,052,274 A 2/1913 Purdy (Continued)

FOREIGN PATENT DOCUMENTS

CN 101002707 A 7/2007 EP 0053936 A2 6/1982 (Continued)

OTHER PUBLICATIONS

Brief Communication—Letter from the Proprietor of the Patent dated Jun. 16, 2020, for the Opposition of European Patent No. EP2731564, 19 pages.


(Continued)

Primary Examiner — Kim M Lewis
(74) Attorney, Agent, or Firm — Knobbe, Martens, Olson & Bear LLP

(57) ABSTRACT

A multi-layered wound dressing including a fibrous absorbent layer for absorbing exudate from a wound site. The wound dressing also includes a support layer configured to reduce shrinkage of at least a portion of the wound dressing.

20 Claims, 5 Drawing Sheets



(51)	Int. Cl.				5,431,643	A	7/1995	Ouellette et al.
	A61M 1/00		(2006.01)	:	5,437,651	A		Todd et al.
	A61F 13/15		(2006.01)		5,447,492			Cartmell et al.
(52)	U.S. Cl.		(5,454,800			Hirt et al.
(32)		161 E	7 2013/00608 (2013.01); A		5,456,660			Reich et al.
	C1 C	AUII	` '		5,465,735 5,470,326		11/1995	Dabi et al.
			<i>2013/1591</i> (2013	5.01)	H1511			Chappell et al.
(56)		Defense	oog Citod		5,480,377			Cartmell et al.
(56)		Reieren	ces Cited		5,486,167		1/1996	Dragoo et al.
	II S	DATENIT	DOCUMENTS		5,487,736	A	1/1996	Van Phan
	0.5.	IAILIVI	DOCOMENTS		5,497,788			Inman et al.
	2,054,768 A	9/1936	Gale, Jr. et al.		5,500,270			Langdon et al.
	2,233,209 A		Herzog		5,505,719			Cohen et al.
	2,280,506 A	4/1942	•		5,509,914 5,514,120			Osborn, III Johnston et al.
	2,682,873 A	7/1954	Idnis et al.		5,520,629			Heinecke et al.
	2,905,174 A	9/1959			5,525,407		6/1996	
	2,992,644 A		Plantinga et al.		5,536,264	A	7/1996	Hsueh et al.
	3,043,301 A 3,156,242 A		Plantinga et al. Crowe, Jr. et al.		5,538,500			Peterson
	3,204,277 A		Sierik et al.		H1585		8/1996	
	3,301,429 A		McClain		5,545,155			Hseih et al.
	3,416,524 A	12/1968			5,549,584 5,549,589		8/1996 8/1996	Horney et al.
	3,529,597 A	9/1970	Fuzak et al.		5,562,107			Lavender et al.
	3,616,154 A		Dow et al.		5,562,646			Goldman et al.
	3,687,136 A		Carmody		5,562,650		10/1996	Everett et al.
	4,212,296 A	7/1980			5,579,765	A	12/1996	Cox et al.
	4,649,909 A 4,798,603 A		Thompson Meyer et al.		5,591,148			McFall et al.
	4,834,735 A		Alemany et al.		5,591,149			Cree et al.
	4,846,164 A	7/1989	•		5,593,395 5,603,707		1/1997	Martz Trombetta et al.
	4,901,714 A	2/1990	Jensen		5,603,946			Constantine
	4,968,181 A		Goldman		5,609,588			DiPalma et al.
	4,973,325 A		Sherrod et al.		5,613,960			Mizutani
	4,988,344 A		Reising et al.		5,614,283	A		Potnis et al.
	4,988,345 A 5,018,515 A		Reising Gilman		5,614,295			Quincy, III et al.
	5,010,515 A 5,021,050 A	6/1991			5,628,736			Thompson
	5,037,409 A		Chen et al.	•	5,632,731		5/1997	
	/ /	11/1991			H1657 5,634,915			Hammons et al. Osterdahl
	5,115,801 A	5/1992	Cartmell et al.		5,636,643			Argenta et al.
	5,124,197 A		Bernardin et al.		5,637,080		6/1997	•
	5,149,334 A		Lahrman et al.		5,643,238		7/1997	•
	5,151,091 A 5,160,328 A		Glaug et al. Cartmell et al.		5,645,081			Argenta et al.
	5,171,391 A		Chmielewski et al.		5,648,142			Phillips
	5,175,046 A	12/1992			5,649,915			Chauvette et al.
	5,176,663 A		Svedman et al.		5,649,916 5,662,599			DiPalma et al. Reich et al.
	5,197,945 A		Cole et al.		5,665,082			Boulanger
	5,217,445 A		Young et al.		5,669,895			Murakami et al.
	5,236,427 A		Hamajima et al.		5,675,079	A	10/1997	Gilman et al.
	5,242,435 A 5,257,982 A		Murji et al.		5,683,354		11/1997	•
	, ,	12/1993			5,700,254			McDowall et al.
	5,281,208 A		Thompson et al.		5,702,356			Hathman Jensen et al.
	5,294,478 A		Wanek et al.		5,704,903			Roach et al.
	5,296,290 A		Brassington		5,713,842		2/1998	
	5,314,743 A		Meirowitz et al.		5,716,703		2/1998	
	5,318,554 A		Young et al.		5,728,084	A		Palumbo et al.
	5,330,456 A 5,336,219 A		Robinson Krantz		5,728,085			Widlund et al.
	5,342,336 A		Meirowitz et al.		5,733,273		3/1998	
	5,348,547 A				5,752,945 5,762,641			Mosley et al. Bewick-Sonntag et al
			Clark et al.		5,788,684			Abuto et al.
	5,356,405 A		Thompson et al.		5,801,107			Everhart et al.
	, ,		Cook et al.		5,810,798			Finch et al.
	5,364,381 A		•		5,817,081	A	10/1998	LaVon et al.
	/ /		Latimer et al. Levesque		5,820,578			Johansen
			Langdon et al.		5,827,213		10/1998	
	r		Thompson et al.		5,827,254			Trombetta et al.
	•		Lemay et al.		5,830,202			Bogdanski et al.
	5,380,294 A	1/1995	Persson		5,837,627			Halabisky et al.
	5,382,245 A		Thompson et al.		5,840,052 5,843,025		11/1998 12/1998	
	5,387,208 A		Ashton et al.		5,843,064		12/1998	
	5,387,209 A 5,397,316 A		Yamamoto et al. LaVon et al.		5,845,572			
	5,401,267 A		Couture-Dorschner et al.		5,865,822			Hamajima et al.
	5,425,725 A		Tanzer et al.		5,865,824			Chen et al.
	, , , 	**			, ,		_	

(56)	Refere	nces Cited	6,776,769 6,783,837		8/2004 8/2004	Smith Creagan et al.
-	U.S. PATENT	DOCUMENTS	6,787,682		9/2004	•
			6,835,192			Guidotti et al.
5,873,867	A 2/1999	Coles et al.	, ,			Liedtke et al.
5,877,097		West et al.	6,841,715			
5,891,120		Chmielewski	6,878,647	BI *	4/2005	Rezai B32B 37/144
5,895,379		Litchholt et al.	6,936,037	R2	8/2005	442/18 Bubb et al.
5,897,541 5,916,507		Uitenbroek et al. Dabi et al.	6,951,553			Bubb et al.
5,925,026		Arteman et al.	6,960,181		11/2005	
5,931,823		Stokes et al.	6,998,511	B2		
5,938,995	A 8/1999	Koltisko, Jr. et al.	7,004,915			Boynton et al.
5,941,863		Guidotti et al.	7,049,478		5/2006	
5,947,945		Cree et al.	7,108,683 7,112,712		9/2006	Zamierowski Ancell
5,951,535 5,961,506		Fujiwara et al. Guidotti et al.	7,118,545		10/2006	
5,968,027		Cole et al.	7,122,023		10/2006	
5,989,478		Ouellette et al.	7,122,712			Lutri et al.
6,022,610		Phan et al.	7,183,345		2/2007	
6,037,518		Guidotti et al.	7,195,624			Lockwood et al. Propp et al.
6,040,493 6,060,638		Cooke et al. Paul et al.	7,294,752		11/2007	11
6,068,620		Chmielewski	7,381,859			Hunt et al.
, ,		Zamierowski	, ,			Chen et al.
6,075,177		Bahia et al.	7,438,705			Karpowicz et al.
6,077,526		Scully et al.	7,476,205			Erdmann Nielsen et al
6,096,015 6,103,953		Yeo et al.	7,507,870 7,511,187		3/2009	Nielsen et al. Kelly
6,103,954		Cree et al. Grondin et al.	7,563,940		7/2009	
6,107,539		Palumbo et al.	7,569,742	B2	8/2009	Haggstrom et al.
6,124,520	A 9/2000	Roberts	7,576,256			Bjornberg et al.
6,124,521		Roberts	7,605,298			Bechert et al.
6,127,595		Makoui et al.	7,615,036 7,622,629		11/2009	Joshi et al.
6,142,982 6,168,849		Hunt et al. Braverman et al.	7,645,269			Zamierowski
6,191,340		Carlucci et al.	7,676,257			Suryanarayanan et al.
6,206,865		Chen et al.	7,708,724			Weston
6,223,383		Vanputten	7,722,582 7,723,561			Lina et al.
6,235,966 6,264,776		Magnusson et al. DiPalma	7,749,531		5/2010 7/2010	Booher
6,294,710		Schmidt et al.	7,759,537			Bishop et al.
6,297,423		Schoenfeldt et al.	7,759,539			Shaw et al.
6,344,036		Ivansson	7,775,998			Riesinger
6,345,623 6,362,390		Heaton et al.	7,776,028 7,779,625			Miller et al. Joshi et al.
6,369,292		Carlucci et al. Strack et al.	7,794,438			Henley et al.
6,372,952		Lash et al.	7,838,719			Hilton, Jr.
6,403,857		Gross et al.	7,838,723			Schmidt et al.
6,468,295		Augustine et al.	7,909,805 7,922,703			Weston Riesinger
6,497,689		Schmidt et al. Goldstein	7,935,066			Shives et al.
6,506,960		Young et al.	7,959,624			Riesinger
6,521,813		Chihani	7,964,766	B2	6/2011	Blott et al.
6,528,696		Ireland	7,976,519			Bubb et al.
6,534,149		Daley et al.	7,988,673			Wright et al.
6,545,194		Schmidt et al.	8,021,347 8,062,272		11/2011	Vitaris et al. Weston
6,551,295 6,570,057		Schmidt et al. Schmidt et al.	8,092,436			Christensen
6,570,058		Fuchs et al.	8,147,468	B2	4/2012	Barta et al.
6,573,424	B1 6/2003	Raidel et al.	8,152,785		4/2012	
6,586,653		Graeme, III et al.	8,162,907			Heagle Lasters and start
6,610,898		Magnusson et al.	8,168,848 8,188,331			Lockwood et al. Barta et al.
6,610,903 6,613,028		Latimer et al. Daley et al.	8,202,261			Kazala, Jr. et al.
6,613,953		Altura	8,212,101		7/2012	
6,613,955		Lindsay et al.	8,241,261			Randolph et al.
6,626,891		Ohmstede	8,246,606			Stevenson et al.
6,630,611		Malowaniec	8,252,971 8,314,283			Aali et al. Kingsford et al.
6,648,862 6,664,439		Watson Arndt et al.	8,328,858			Barsky et al.
6,683,229		Ehrnsperger et al.	8,372,050			Jaeb et al.
6,685,681		Lockwood et al.	8,376,972		2/2013	Fleischmann
6,706,940		Worthley	8,382,731			Johannison
6,719,742		McCormack et al.	8,403,899			Sherman
6,727,403 6,752,794		Ehrnsperger et al. Lockwood et al.	8,404,921 8,425,478		3/2013 4/2013	Lee et al.
6,762,337		Boukanov et al.	8,444,611			Wilkes et al.
,	B1 7/2004		<i>'</i>			Coulthard et al.

(56)	References Cited			2003/0150551 A1		Baker Cools at al
U.S.	U.S. PATENT DOCUMENTS			2003/0157857 A1 2003/0171729 A1 2003/0180341 A1	9/2003	Cook et al. Kaun et al. Gooch et al.
8,481,804 B2*	7/2013	Timothy A61F 13/00021		2003/0190854 A1	* 10/2003	Stagray B32B 37/1284 442/381
8,513,481 B2		Gergely et al.	3	2003/0199800 A1 2003/0208175 A1		
8,535,296 B2 8,545,466 B2		Blott et al. Andresen et al.		2003/0203173 A1 2003/0212359 A1		
8,663,198 B2		Buan et al.		2003/0225383 A1		Glaug et al.
8,680,360 B2 8,708,998 B2		Greener et al.		2004/0019338 A1 2004/0019339 A1		Litvay et al. Ranganathan et al.
8,715,256 B2		Greener		2004/0019340 A1	1/2004	McBride
8,722,961 B2		Vinton et al.		2004/0019342 A1 2004/0024102 A1		Nagasuna et al. Hayes B32B 7/12
8,764,732 B2 8,791,316 B2		Hartwell Greener		2004/0024102 A1	2/2004	524/425
8,795,247 B2	8/2014	Bennett et al.		2004/0024375 A1		Litvay
8,801,685 B2 8,814,842 B2		Armstrong et al. Coulthard et al.		2004/0033750 A1 2004/0049146 A1		Everett et al. Kolte et al.
8,843,327 B2		Vernon-Harcourt et al.		2004/0054343 A1	3/2004	Barnett et al.
8,916,742 B2				2004/0054344 A1 2004/0065420 A1		Roettger et al. Graef et al.
8,986,270 B2 9,033,942 B2		Johannison et al. Vess		2004/0005420 A1 2004/0076662 A1		Riesinger
9,061,095 B2	6/2015	Adie et al.		2004/0078016 A1		Baker
9,220,822 B2 9,254,353 B2		Hartwell Locke et al.		2004/0087927 A1 2004/0111074 A1		Suzuki Eliasson
9,265,665 B2		Robinson et al.		2004/0138602 A1	7/2004	Rossen
9,579,411 B2		Addison et al.		2004/0177935 A1 2004/0181199 A1		Hamed et al. Moberg-Alehammar et al.
2001/0000795 A1 2001/0016985 A1		Bolian, II et al. Insley et al.		2004/0101199 A1 2004/0204696 A1		
2001/0018308 A1	8/2001	Quick et al.		2004/0230173 A1		Barge et al.
2001/0027302 A1 2001/0027305 A1		Glaug et al. Raidel et al.		2004/0230184 A1 2004/0241214 A1		Kirkwood et al.
2001/002/303 A1		Kim et al.		2004/0243042 A1	12/2004	Lipman
2001/0051178 A1		Blatchford et al.		2004/0243080 A1 2004/0243081 A1		Baer Suzuki et al.
2001/0053904 A1 2002/0007167 A1	12/2001 1/2002	Dan et al.		2004/0253894 A1		Fell et al.
	1/2002	Graef et al.		2004/0254552 A1		-
2002/0019602 A1 2002/0019614 A1	2/2002 2/2002	Geng Woon et al.		2005/0008825 A1 2005/0013992 A1		Casey et al. Azad et al.
2002/0026166 A1	2/2002	Graef et al.		2005/0015036 A1		Lutri et al.
2002/0034914 A1 2002/0035354 A1		De Leon et al. Mirle et al.		2005/0049566 A1 2005/0079361 A1		Vukos et al. Hamed et al.
2002/0062113 A1		Thomas et al.		2005/0096616 A1		Arora et al.
2002/0064639 A1 2002/0087136 A1		Rearick et al. Widlund		2005/0112979 A1 2005/0119631 A1		Sawyer et al. Giloh et al.
2002/008/130 A1 2002/0090511 A1		Smith et al.		2005/0136773 A1	6/2005	Yahiaoui et al.
2002/0110672 A1 2002/0123728 A1		Muratore-Pallatino et al.		2005/0165371 A1 2005/0215965 A1		Giacometti Schmidt et al.
2002/0123728 A1 2002/0133132 A1		Graef et al. Copat et al.		2005/0215967 A1	_ ,	Toro et al.
2002/0150678 A1	10/2002	Cramer et al.		2005/0222547 A1 2005/0228353 A1		Beruda et al. Thomas
2002/0165509 A1 2002/0176964 A1		Baer et al. Koslow		2005/0228555 A1 2005/0261649 A1		
2002/0177831 A1	11/2002	Daley et al.		2005/0267429 A1		
2002/0180092 A1 2002/0183704 A1		Abba et al. Fields et al.		2006/0003604 A1 2006/0009744 A1		Angerpointner Erdman et al.
2002/0103/04 A1	1/2003			2006/0020250 A1	1/2006	Chester et al.
2003/0045707 A1		West et al.		2006/0058750 A1 2006/0069366 A1		Di Girolamo et al. Cole
2003/0045825 A1 2003/0050617 A1		Etheredge, III Chen et al.		2006/0069367 A1		Waksmundzki et al.
2003/0069563 A1	4/2003	Johnson		2006/0069375 A1		Waksmundzki et al.
2003/0070780 A1 2003/0073967 A1		Chen et al. Wahlstrom et al.		2006/0122548 A1 2006/0122572 A1		Abrams Suarez
2003/0088229 A1	5/2003	Baker et al.		2006/0153904 A1		Smith et al.
2003/0088231 A1 2003/0093044 A1		Yoshimasa et al. Wahlstrom et al.		2006/0161122 A1 2006/0178650 A1		Erdman et al. Hakansson et al.
2003/0093044 A1		Schmidt et al.		2006/0184147 A1	8/2006	Hamed
2003/0097105 A1		Chen et al.		2006/0206047 A1 2006/0206073 A1		Lampe et al. Crane et al.
2003/0097113 A1 2003/0105442 A1		Molee Johnston et al.		2006/0206073 A1 2006/0206074 A1		Bernal et al.
2003/0114816 A1	6/2003	Underhill et al.		2006/0241542 A1		Gudnason et al.
2003/0114818 A1 2003/0114821 A1		Benecke et al. Underhill et al.		2006/0282028 A1 2007/0003604 A1		Howard et al. Jones
2003/0120249 A1	6/2003	Wulz et al.		2007/0021697 A1	1/2007	Ginther et al.
2003/0121588 A1 2003/0124311 A1		Pargass et al. Cree et al.		2007/0073254 A1 2007/0078467 A1		Ponomarenko et al. Mullen
2003/0124311 A1 2003/0134559 A1		Delzer et al.		2007/0078467 A1 2007/0100308 A1		Miyairi
2003/0135174 A1	7/2003	Benecke et al.		2007/0142804 A1	6/2007	Bernard
2003/0135177 A1	7/2003	Baker		2007/0167096 A1	7/2007	Scott

(56)		Referen	ces Cited		1/0178375			Forster	
	U.S.	PATENT	DOCUMENTS	201	1/0183109 1/0184364	A1	7/2011	Seyler et al. Biggs et al.	
2007/0167884	A 1	7/2007	Mangrum et al.		1/0184370 1/0208145			Seyler et al. Zhang et al.	
2007/0107884			Chakravarty et al.	201	1/0213286	A 1	9/2011	Riesinger	
2007/0225663			Watt et al.		1/0218509 1/0223413			Dontas Herfert et al.	
2007/0254550 2007/0270070		11/2007 11/2007	Hamed et al.		1/0223413			Simmons et al	•
2007/0270070			LaGreca	201	1/0238026	A 1	9/2011	Zhang et al.	
2008/0004581			Babusik et al.		1/0245788 1/0247636		10/2011 10/2011	Marquez Cana Pollack	da
2008/0015532 2008/0058691			Waksmundzki Sorensen		1/024/030			Locke et al.	
2008/0038031			Morrell-Schwartz	201	1/0268932	A1	11/2011	Catalan et al.	
2008/0090050			Seyler et al.		2/0004632 2/0045639			Zhang et al. Whitmore et al.	1
2008/0091152 2008/0114317		4/2008 5/2008	Asherman Seyler		2/0043639			Schroeder et a	
2008/01119586			Byerly et al.		2/0071848			Zhang et al.	
2008/0147024			Potts et al.		2/0095426 2/0101465			Visscher et al. McGuire, Jr.	
2008/0167592 2008/0243100		7/2008	Greer Wu et al.		2/0123311			,	endrickson et al.
2008/0254103			Harris et al.		2/0130332			Cotton et al.	
2008/0255533			Wu et al.		2/0136329 2/0143158			Carney Yang et al.	
2008/0275409 2008/0312621			Kane et al. Hundorf et al.		2/0172778			Rastegar et al.	
2008/0312622			Hundorf et al.		2/0197229			Buan et al.	
2009/0062760			Wright et al.		2/0203145 2/0220968			Nilsson Confalone et a	1
2009/0065014 2009/0076472			Nagata Goldwasser et al.		2/0232502			Lowing	4.
2009/01/12175			Bissah et al.		2/0238932			Atteia et al.	•
2009/0204087			Herfert et al.		2/0283529 2/0302440			Marchand et al Theliander et a	
2009/0216168 2009/0227935			Eckstein Zanella et al.		2/0302440			Rottger et al.	L1.
2009/0227969			Jaeb et al.		2/0310186			Moghe et al.	
2009/0240218			Braga et al.		2/0310197 2/0330252			Thomas Stokes et al.	
2009/0281471 2009/0293887			Iwahashi et al. Wilkes et al.		2/0330252			Robinson et al	•
2009/0299251		12/2009			3/0012902			Rovaniemi	1 C1T 10 (500
2009/0299255			Kazala, Jr. et al.	201	3/0197460	Al*	8/2013	Shaw	A61F 13/539 604/368
2009/0299340 2010/0010461			Kazala, Jr. et al. Herfert et al.	201	4/0114268	A 1	4/2014	Auguste et al.	004/300
2010/0030171	A1	2/2010	Canada et al.		5/0159066			Hartwell et al.	
2010/0036334 2010/0036342			Heagle et al. Carlucci et al.		5/0174304 8/0125720		5/2018	Askem et al. Pigg	
2010/0030342			Kauschke et al.		9/0110932			Mumby et al.	
2010/0055158			Vitaris et al.	201	9/0216651	A1	7/2019	Vitaris et al.	
2010/0069858 2010/0084074		3/2010 4/2010	McClernon et al.		ΕO	DEIG	NI DATE	NT DOCUME	NITC
2010/0087767			McNeil		ro.	KETO.	N IAIL.	INT DOCUME	
2010/0106120		4/2010		EP			119 A2	7/1985	
2010/0106121 2010/0121286		4/2010 5/2010	Locke et al.	EP			251 A1	5/1993	
2010/0121298		5/2010	Seyler et al.	EP EP			105 A1 894 A2	10/1994 12/1996	
2010/0122417 2010/0125234		5/2010 5/2010	Vrzalik et al.	EP		0875	224 A1	11/1998	
2010/0123234			Coulthard et al.	EP EP			726 A1 290 A1	9/1999 6/2000	
2010/0168695			Robles et al.	EP			278 A2	11/2000	
2010/0179463 2010/0217177			Greener et al. Cali et al.	EP		1066	809 A2	1/2001	
2010/021/17/			Aali et al.	EP EP			328 A2 156 A1	5/2003 9/2004	
2010/0256584		10/2010	•	EP		1 314		2/2010	
2010/0256586 2010/0262091		10/2010 10/2010	Bergstrom et al.	EP			011 A1	3/2010	
2010/0202031			Robinson et al.	EP EP			721 A1 915 B1	9/2011 10/2015	
2010/0318047			Ducker et al.	GB			917 A	6/1994	
2010/0318052 2010/0324516			Ha et al. Braga et al.	GB			228 A	4/2001	
2010/0324310			Eckstein et al.	GB GB			422 A 423 A	8/2007 8/2007	
2011/0052664			Tennican et al.	GB			947 A	10/2012	
2011/0054422 2011/0059329			Locke et al. Dobrawa et al.	GB	~	2525		10/2015	
2011/0059329			Bissah et al.	JP JP			655 A 185 A	5/2001 10/2007	
2011/0092927			Wilkes et al.	JP			497 A	5/2008	
2011/0098621 2011/0106030			Fabo et al. Scholz	WO			161 A1	8/1991	
2011/0100030			Bharti et al.	WO WO			162 A1 778 A1	8/1991 2/1993	
2011/0125119	A1	5/2011	Weismantel et al.	WO			781 A1	2/1993	
2011/0137222		6/2011		WO			726 A1	6/1993 5/1005	
2011/0152813	Al	0/2011	Ellingson	WO	WC	J - Y313	042 A1	5/1995	

(56)	Reference	ees Cited	WO WO-2011019476 A1 2/2011
	FOREIGN PATEN	NT DOCUMENTS	WO WO-2011023275 A1 3/2011 WO WO-2011023650 A1 3/2011
****	TTTO 0 - 1 1 - 1	- (4.00-	WO WO 2011/057240 5/2011 WO WO-2011058311 A1 5/2011
WO	WO-9513779 A1	5/1995	WO WO-2011038311 A1 3/2011 WO WO-2011063818 A1 6/2011
WO	WO-9514451 A1	6/1995	WO WO-2011003818 A1 0/2011 WO WO-2011113728 A1 9/2011
WO	WO-9516424 A1	6/1995	WO WO-2011113728 A1 9/2011 WO WO-2011128651 A1 10/2011
WO	WO-9607783 A1	3/1996	WO WO-2011128031 A1 10/2011 WO WO-2011152368 A1 12/2011
WO	WO-9621410 A1	7/1996	WO WO-2011132300 A1 12/2011 WO WO-2012009370 A2 1/2012
WO	WO-9711658 A1	4/1997	WO WO-2012005570 A2 1/2012 WO WO-2012035787 A1 3/2012
WO	WO-9714384 A1	4/1997 5/1008	WO WO-2012033707 AT 3/2012 WO WO-2012074512 A1 6/2012
WO	WO-9820916 A1	5/1998	WO WO-2012146656 A1 11/2012
WO	WO-9822279 A1	5/1998 2/1000	WO WO-2012150235 A1 11/2012
WO WO	WO-9904830 A1 WO-9939671 A1	2/1999 8/1999	WO WO-2012168298 A1 12/2012
WO	WO-9939071 A1 WO-9945876 A1	9/1999	WO WO-2013014317 A1 1/2013
WO	WO-9945878 A1	9/1999	WO WO-2013029652 A1 3/2013
WO	WO-9943878 A1 WO-9956687 A1	11/1999	WO WO-2013060732 A1 5/2013
WO	WO-9930087 A1 WO-0000016 A1	1/2000	WO WO-2013175306 A2 11/2013
WO	WO-000010 A1 WO-0000127 A1	1/2000	WO WO-2014003957 A1 1/2014
WO	WO-0000127 A1 WO-0000129 A1	1/2000	WO WO 2017/174332 10/2017
WO	WO-0000129 A1	1/2000	WO WO 2018/077872 5/2018
WO	WO-0000130 A1	1/2000	WO WO-2019020550 A2 1/2019
WO	WO-0040190 A1	7/2000	ZA 9605526 B 2/1997
WO	WO-0042957 A1	7/2000	
WO	WO-0059438 A1	10/2000	OTHER PUBLICATIONS
WO	WO-0172251 A1	10/2001	OTHER PUBLICATIONS
WO	WO-0190465 A2	11/2001	International Proliminary Popart on Patentability for Application
WO	WO-0217840 A1	3/2002	International Preliminary Report on Patentability for Application
WO	WO-0224132 A2	3/2002	No. PCT/EP2017/077154, dated May 9, 2019, 8 pages.
WO	WO-0226180 A1	4/2002	International Preliminary Report on Patentability for Application
WO	WO-0238096 A2	5/2002	No. PCT/GB2012/000587, dated Jan. 23, 2014, 12 pages.
WO	WO-02076379 A2	10/2002	International Search Report and Written Opinion for Application
WO	WO-03057307 A1	7/2003	No. PCT/GB2012/000587, dated Oct. 8, 2013, 17 pages.
WO	WO-03073971 A2	9/2003	KCI Licensing Inc, "Prevena TM Incision Management System—
WO	WO-2004043321 A1	5/2004	Clinician Guide—Instructions for Use," 390061 Rev D, Jan. 2010,
WO	WO-2004073566 A1	9/2004	10 pages.
WO	WO-2004098474 A1	11/2004	KCI Licensing Inc, "Prevena TM Incision Management System—
WO	WO-2006105305 A1	10/2006	Clinician Guide—Instructions for Use," 390153-WEB Rev B, Jan.
WO	WO-2007035038 A1	3/2007	2010, 12 pages.
WO	WO-2007040606 A2	4/2007	KCI Licensing, "Prevena TM Incision Management System—Patient
WO	WO-2007077214 A1	7/2007	Guide", 390064 Rev D, Jan. 2010, 4 pages.
WO	WO-2007077216 A1	7/2007	KCI Licensing, "Prevena TM Incision Management System—Patient
WO	WO-2007082538 A1	7/2007	Guide," 390152-WEB C, Jan. 2011, 6 pages.
WO	WO-2007116347 A2	10/2007	KCI Licensing, Prevena TM Incision Management System, Jun. 22,
WO	WO-2007134516 A1	11/2007	2010, in 2 pages.
WO WO	WO-2008049277 A1	5/2008 11/2008	Notice of Opposition—Statement of Facts and Evidence for the
	WO-2008131895 A1	11/2008	European Patent No. 2731564, mailed Jan. 22, 2020, 12 pages.
WO	WO-2009019227 A2	2/2009	Smith & Nephew, Allevyn Gentle Border Multisite, Jun. 2011, 2
WO	WO-2009019229 A2	2/2009	
WO	WO-2009103031 A1	8/2009	pages. Smith and Nephew Inc., "Allevyn Wound Dressings Pamphlet,"
WO	WO-2009152021 A2	12/2009	
WO	WO-2010032951 A2	3/2010	2008, 2 pages. International Search Depart and Written Opinion, re DCT Applies
WO	WO-2010072395 A1	7/2010	International Search Report and Written Opinion, re PCT Applica-
WO	WO-2010082872 A1	7/2010	tion No. PCT/EP2017/077154, dated Dec. 1, 2017.
WO	WO-2010089448 A1	8/2010	
\mathbf{W}	$WO_{-}2010130026 A 1$	12/2010	* cited by examiner

^{*} cited by examiner

WO

WO-2010139926 A1

12/2010






Fig. 1








Fig. 3B




Fig. 4




Fig. 5




Fig. 6




Fig. 7

MULTI-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. national stage application of International Patent Application No. PCT/EP2017/077154, filed on Oct. 24, 2017, which claims priority to GB Application No. 1618298.2, filed Oct. 28, 2016, entitled MULTI- ¹⁰ LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE.

BACKGROUND

Field

The present invention relates to a multi-layered wound dressing and a method of manufacturing such a wound dressing. In particular, but not exclusively, embodiments of 20 the present invention relate to a multi-layered wound dressing having a fibrous absorbent layer that can resist shrinkage even under extreme sterilisation methods and storage conditions, have improved aesthetics and mechanical strength and thereby increase consistency of product over its shelf ²⁵ life.

Description of the Related Art

Wound dressings can be formed with a liquid-imperme- 30 able top layer (outer layer, furthest from the wound), which prevents wound exudates striking through and leaking from the dressing. The top layer is often also gas permeable and liquid vapour permeable, to help minimise maceration to the wound.

In some known wound dressings, the liquid-impermeable top layer can be susceptible to wrinkling (wrinkling includes but is not limited to inconsistent appearance, crinkles, creases textured surface). Wrinkling may occur whilst the wound dressing is packaged in a sterile packaging, and may 40 be due to shrinking of one or more wound dressing layers over time. This may be due to the type of packaging and sterilisation method chosen. It could be perceived by a medical practitioner that if wrinkling is present the product has been compromised. Thus, it may not be possible to 45 determine whether the wound dressing is still suitable for use. Wrinkling of the top layer may also occur whilst the wound dressing is in use. A wrinkled wound dressing is also visually unappealing to a patient.

Wound dressings often require a product shelf life of as 50 long as possible, typically 5 years, so it is desirable to produce a wound dressing in which the liquid impermeable top layer is not as likely to wrinkle, become inconsistent in appearance or change aesthetics over time.

EP 1,314,410 discloses a multi-layered wound dressing 55 having top film layer, but does not disclose any way of reducing or preventing shrinkage or wrinkling of the dressing.

SUMMARY

According to a first aspect of the present invention there is provided a multi-layered wound dressing comprising:

- a fibrous absorbent layer for absorbing exudate from a wound site; and
- a support layer configured to reduce shrinkage of at least a portion of the wound dressing.

According to a second aspect of the present invention there is provided a method of manufacturing a multi-layered wound dressing, the method comprising:

forming a support layer;

forming a fibrous absorbent layer for absorbing exudate from a wound site; and

laminating the support layer and the absorbent layer together to form the wound dressing;

wherein the support layer is configured to reduce shrinkage of at least a portion of the wound dressing.

According to a third aspect of the present invention there is provided a method of treating a wound comprising placing a multi-layered wound dressing according to any embodiment disclosed herein over a wound.

According to a fourth aspect of the present invention there is provided a method of providing negative pressure wound therapy to a wound, the method comprising:

placing a multi-layered wound dressing according to any embodiment disclosed herein over a wound;

forming a fluid flow path between the wound dressing and a negative pressure source; and

operating the negative pressure source to provide negative pressure to the wound.

According to a fifth aspect of the present invention there is provided a method of operating a negative pressure wound system, the method comprising:

operating a negative pressure source fluidically connected to a multi-layered wound dressing according to any embodiment disclosed herein, the wound dressing configured to be positioned over a wound.

According to a sixth aspect of the present invention there is provided a negative pressure wound therapy kit comprising a multi-layered wound dressing according to any 35 embodiment disclosed herein and a negative pressure source configured to be fluidically connected to the wound dressing.

According to another aspect there is provided a multilayered wound dressing comprising:

- a fibrous absorbent layer for absorbing exudate from a wound site; and
- a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

wherein the support layer comprises a net, the net comprises a geometric structure having a plurality of substantially geometric apertures extending therethrough; and

the geometric structure comprises a plurality of bosses substantially evenly spaced and joined by polymer strands to form the substantially geometric apertures between the polymer strands.

According to another aspect there is provided a multilayered wound dressing comprising:

- a fibrous absorbent layer for absorbing exudate from a wound site; and
- a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

wherein the net is formed from high density polyethylene. According to another aspect there is provided a multilayered wound dressing comprising:

- a fibrous absorbent layer for absorbing exudate from a wound site; and
 - a support layer configured to reduce shrinkage of at least a portion of the wound dressing,
- wherein the support layer has a tensile strength from 0.05 to 65 0.06 Nm.

According to another aspect there is provided a multilayered wound dressing comprising:

- a fibrous absorbent layer for absorbing exudate from a wound site; and
- a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

wherein the support layer is bonded to fibres in a top surface of the absorbent layer,

the support layer further comprises a bonding layer, wherein the support layer is heat laminated to the fibres in the absorbent layer via the bonding layer; and

wherein the bonding layer comprises a low melting point 10 ethylene-vinyl acetate adhesive.

Certain embodiments of the invention provide the advantage that at least part of the wound dressing is less likely to shrink over time compared to known wound dressings.

Certain aspects of the invention provide a wound dressing 15 in which wrinkling in a layer or layers of a wound dressing, e.g. a liquid impermeable film layer is prevented or reduced.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:

FIG. 1 is a schematic diagram of a section of an example of a wound dressing;

FIG. 2 is a schematic diagram of an example of a support layer;

FIG. 3A is a schematic diagram of a section of another example of a wound dressing;

FIG. 3B is a perspective view of the wound dressing of 30 FIG. 3A;

FIG. 4 is a flow diagram of an example of a method of manufacturing the wound dressing of FIG. 3A;

FIG. **5** is a schematic diagram of a further example of a wound dressing; and

FIG. 6 is a schematic diagram of a yet further example of a wound dressing.

FIG. 7 is a schematic diagram of an example of a negative pressure wound therapy system.

In the drawings like reference numerals refer to like parts. 40 FIG. 1 shows an example of a multi-layer wound dressing 100. The wound dressing 100 includes a liquid impermeable film layer 102 located at the top of the wound dressing 100. In use, the film layer 102 is the top layer of the wound dressing 100, most distal from a wound site.

The film layer 102 is also gas and vapour permeable to allow for evaporation of fluid or wound exudate from the wound dressing 100, and help prevent maceration of the wound. In this example, the film layer 102 is formed from a polyurethane blend, though other suitable materials may 50 include other polymeric materials, for example polyethylene, or polypropylene.

An absorbent layer 108 underlies the film layer 102. The absorbent layer 108 has a fibrous structure for absorbing exudate from a wound site. In this example, the absorbent layer 108 includes superabsorbent fibres. The absorbent layer 108 also includes other fibres. In this example, the absorbent layer includes superabsorbent fibres, viscose fibres and polyester fibres.

In this example, the absorbent layer **108** includes around 60 40% superabsorbent fibres, 40% viscose fibres, and 20% polyester fibres. In other examples, the absorbent layer may include around 0-50% superabsorbent fibres, 0-100% viscose fibres and 0-50% polyester fibres. Suitable superabsorbent fibres include crosslinked acrylate copolymer fibres that 65 are partially neutralized to sodium salt however other superabsorbent fibres are available. The absorbent layer **108** may

4

be manufactured using a needling process in which the fibres are mechanically tangled together.

In other examples, the absorbent layer may include other ratios of superabsorbent, viscose and polyester fibres. For example, the absorbent layer may include around 50% superabsorbent fibres, 35% viscose fibres and 20% polyester fibres. Alternatively, the absorbent layer may include 40% superabsorbent fibres and 60% viscose fibres.

The film layer 102 is located over the absorbent layer 108 so that wound exudate collected in the absorbent layer 108 can evaporate out of the wound dressing 100 through the film layer 102.

A support layer 106 is located between the film layer 102 and the absorbent layer 108. The support layer 106 helps to reinforce the structure of the absorbent layer 108 and thereby reduce shrinkage of the wound dressing 100. The support layer 102 also helps to provide extra mechanical strength to the film layer 102 to reduce or prevent wrinkling of the film layer 102 over time. The mechanical strength also reduces the chance of the dressing deforming or rolling up causing a pressure point.

Aptly, the support layer **106** is configured to have a tensile strength from 0.05 to 0.06 Nm to provide mechanical strength to the surrounding layers (e.g. the film layer **102** and the absorbent layer **108**) without compromising the flexibility of the wound dressing **100**. The support layer **106** may have a thickness of from 50 to 150 μm. Aptly, the support layer **106** may have a thickness of around 100 to 110 μm.

Referring to FIG. 2, the support layer 106 includes a net 200 configured to reduce shrinkage of the wound dressing 100. Aptly, the net 200 is configured to reduce shrinkage of the absorbent layer 108 and/or the film layer 102 to help reduce wrinkling of the film layer 102.

In this example, the net 200 has a substantially hexagonal (or honeycomb) structure 204 including a plurality of substantially triangular shaped apertures 202 extending therethrough.

The hexagonal structure 204 is formed from a plurality of dots (or bosses) 206 joined by polymer strands 208. The dots 206 are substantially evenly spaced with respect to each other. Each dot forms a vertex of the hexagonal pattern in the structure 204. Each dot 206 is joined to six surrounding dots 206 by polymer strands 208. That is, six polymer strands 208 extend from each dot 206 and each connect to a respective surrounding dot 206 to form the hexagonal structure 204 having triangular shaped apertures 202 between the polymer strands 208.

Each of the triangular shaped apertures 202 may have an area A of from 0.005 to 0.32 mm². This allows liquid vapour from a wound to pass freely through the apertures, whilst still providing sufficient strength to the support layer 106.

It can also be said that the structure 204 is a structure comprising a plurality of strands or struts that are joined to form a plurality of triangles. In this example the triangles tessellate in rows. It will be appreciated that the strands or struts may be arranged in other formations, for example squares, diamonds or rectangles with different geometries and therefore differing open areas.

In this example, the support layer 106 is located directly adjacent the absorbent layer 108. As such, the support layer 106 can effectively provide additional mechanical strength to fibres in the top surface of the absorbent layer 108. This can help prevent movement of the fibres and reduce shrinking of the absorbent layer 108.

Aptly, the support layer 106 is bonded to the fibres in the top surface of the absorbent layer 108. This can help to lock the fibres in position and prevent or reduce any movement.

In this example, the support layer 106 further includes a bonding layer for heat laminating the net 200 to the absorbent layer 108. The support layer 106 is thus heat laminated to fibres in the absorbent layer 108 via the bonding layer.

The bonding layer contained within the net has a lower 5 melting temperature than the net 200 so that the support layer 106 can be heat laminated to the absorbent layer 108 whilst maintaining the structure of the net 200. The bonding layer can be formed from a low melting point polymer, for example a low melting point ethylene-vinyl acetate, whilst the net 200 may be formed from a high density polyethylene, which melts at a higher temperature than the bonding layer. Other polymers having a lower melting point than the net 200 may also be suitable. For example the bonding layer may be a separate layer or alternatively include an ethylene- 15 acrylate or thermoplastic polyurethane based adhesive.

The net **200** and the bonding layer can be coextruded to form the support layer 106. Aptly, the bonding layer is extruded with a similar structural shape to the net 200, so that the apertures 202 in the net 200 are not obstructed by the 20 bonding layer. This helps to ensure that exudate the absorbent layer 108 can pass through the support layer and evaporate out of the wound dressing 100 through the film layer **102**.

FIG. 3 illustrates another example of a multi-layered 25 wound dressing 300. The wound dressing 300 includes a film layer 302, support layer 306 and absorbent layer 308, the same as the film layer 102, support layer 106 and absorbent layer 108 described in relation to FIG. 1.

layer 304, located between the film layer 302 and the support layer 306, for attaching the film layer 302 to the support layer 306. The first adhesive layer 304 is a hot melt adhesive applied to a wound facing side (underside) of the film layer 302. Aptly, the first adhesive layer 304 is pattern coated onto 35 the film layer 302, to include holes, so that gas and liquid vapour can pass through holes in the first adhesive layer 304. In other examples the film layer 302 may be laminated (e.g. heat laminated) directly onto the support layer 306 without the need for an adhesive layer 304 in between.

In this example, the wound dressing 300 also includes a foam layer 312, which is a fluid transport layer. The foam layer 312 is located under the absorbent layer 306. The foam layer 312 acts to draw fluid away from a wound site and transport the fluid to the absorbent layer **308**. The foam layer 45 may be formed from an open cell polyurethane foam and other options are available, as will be recognised by those skilled in the art.

An adhesive web layer 310 is located between the foam layer 312 and the absorbent layer 308 to adhere the foam 50 layer 312 to the absorbent layer 308. The adhesive web layer may be formed from bicomponent polypropylene/polyethylene fibres. Such bicomponent fibres are known in the art, so for brevity will not be discussed in detail. The adhesive web layer 310 includes a plurality of apertures extending therethrough to allow for passage of exudate from the foam layer 312 to the absorbent layer 108.

The wound dressing 300 also includes a wound contact layer 320, which includes a perforated film 316. The perforated film 316 is located under the foam layer 312 and 60 helps to prevent the wound dressing 300 from attaching to the wound as the wound heals. For example, where the wound dressing 300 includes the foam layer 312, the perforated film 316 can prevent new tissue from growing into cells of the foam layer 312. In other examples, the foam 65 layer 312 may not be present and the perforated film 316 can help prevent fibres of the absorbent layer 308 from becom-

ing embedded in the wound. Perforations in the perforated film 316 are aptly substantially uniformly distributed and are of suitable size to allow passage of exudate into the wound dressing 300, e.g. with holes having a diameter of 1-2.5 mm. The perforated film **316** is aptly formed from polyurethane.

The wound contact layer 320 may also include an adhesive 318 located under the perforated film 316 (i.e. on the wound facing side of the perforated film 316) for adhering the wound dressing 300 to the skin. In this case the adhesive is silicone 318 and is aptly spread onto the underside of the perforated film with a coat weight of around 30-200 g/m². In some other examples, an additional attachment element, for example bandages, strips of tape, or compression bandages may be used to secure the wound dressing 300 to the patient.

The top side of the perforated film **316** (i.e. the side distal from the wound) may be coated with a further adhesive layer **314**. The further adhesive layer **314** adheres the wound contact layer 320 to the foam layer 312. Aptly, the further adhesive layer 314 may be an acrylic adhesive, though other suitable adhesives may also be used. In other examples the wound contact layer 320 may be laminated (e.g. heat laminated) directly to the foam layer 312, without the need for the further adhesive layer **314** in between.

FIG. 4 illustrates an example of a method of manufacturing the wound dressing 300. The method is not limited to the steps shown and, as described above, may include additional steps. The method also is not limited to the order shown in FIG. 4. As will be appreciated by those skilled in the art, several of the method steps shown may be performed The wound dressing 300 also includes a first adhesive 30 in a different order. In some embodiments, the wound dressing 300 is manufactured by forming each of the layers, and assembling the layers in the correct order, before heat laminating them together.

> The film layer 302 may be formed by extrusion. At step **401**, the first adhesive layer **304** is applied to the film layer. Aptly, the first adhesive layer 304 is pattern coated onto the underside of the extruded film layer 302.

> At step 402 the support layer 306 and the absorbent layer 308 are heat laminated together to form a single piece. At step 403 the film layer 302 and first adhesive layer 304 are heat laminated to the support layer 306 on the top side of the single piece and the adhesive web layer 310 and foam layer 312 are heat laminated to the absorbent layer 308. Whilst the layers have been described as being heat laminated together in a specific order, the layers may be separately laminated together or laminated together all at the same time.

> At step 404 the wound contact layer 320 is formed by coating one side of a film layer with the silicone adhesive layer 314, and coating the other side of the film layer with a further adhesive layer **314**. The film layer is then perforated at step 405 (e.g. by needle punching), to form the wound contact layer 320 including the perforated film 316, the silicone adhesive layer 314 for contacting the wound and the further adhesive layer **314**. Alternatively, the film layer may be perforated before adding the further adhesive layer **314**.

> The wound contact layer may then be laminated (e.g. with heat, ultrasonic and/or radio frequency welding) to the underside of the foam layer 312 to form the wound dressing **300**, as shown at step **406**.

> At step 407 a removable cover may be applied to the underside of the silicone adhesive layer **318**. This cover can be removed before the wound dressing 300 is applied to a patient.

> At step 408 the wound dressing 300 may be cut into separate wound dressing pieces, each suitably sized for an intended application.

In another example, as shown in FIG. 5, the film layer 502 may have a larger surface area than the remainder of the wound dressing 500 so that it extends further outwardly than the other layers of the wound dressing. The wound-facing (underside) of the film layer may be coated with a pressure sensitive adhesive 504 (or other suitable adhesive) for sticking the dressing to the patient around the wound periphery. The pressure sensitive adhesive 504 may also adhere the film layer 502 to the support layer 506 of the wound dressing 500. The wound dressing may also include an absorbent layer 508, adhesive web layer 510, foam layer 512, further adhesive layer 514 and wound contact layer 520. Each of the layers in this example may be similar to corresponding layers described above in relation to FIGS. 3A and 3B, so for brevity will not be described again in detail.

In this example, the wound dressing may be manufactured following steps 401 to 407 described above. However, instead of cutting the dressing to size (step 408) each wound dressing may be made individually with each layer cut or 20 formed to the desired size prior to laminating all the layers together so that the final wound dressing has a film layer larger than the other layers.

In a further example, as shown in FIG. 6, both the wound contact layer 620 and the film layer 602 may extend beyond 25 the remaining layers of the wound dressing 600. The wound contact layer 620 and the film layer may be adhered together around the periphery (e.g. via an adhesive layer **604**), so that the remaining layers of the wound dressing are sandwiched between the wound contact layer 620 and the film layer 602. In other words the support layer 606, the absorbent layer 608, the adhesive web layer 610, and the foam layer 612 may be sealed within a cavity 622 between the film layer 602 and the wound contact layer 620. In this example, a further adhesive layer **614** adheres the foam layer **612** to the wound 35 contact layer 620, though in other examples the further adhesive layer **614** may not be required. Each of the layers in this example may be similar to corresponding layers described above in relation to FIGS. 3A and 3B, so for brevity will not be described again in detail.

The wound dressing 600 in this example may be manufactured similarly to the wound dressing 300, as described above, but with the film layer 602 and the wound contact layer 620 being laminated together around the periphery (e.g. via the adhesive layer 604) to sandwich the remaining 45 layers between the film layer 602 and the wound contact layer 620. Alternatively, the film layer 602 may be directly laminated around the periphery (e.g. heat laminated) to the wound contact layer 620, without the need for the additional adhesive layer 604.

Although the wound dressings 300, 500, 600 have been described having several adhesive layers, one or more of these layers may not be present. For example, the perforated film itself may be formed from a hot melt adhesive material so that it can be directly heat laminated onto the foam layer, 55 in which case the further adhesive layer may not be needed. In another example, the adhesive web layer may not be present if the foam and absorbent layers are adhered in another way. For example, the foam and absorbent layers may be directly chemically bonded together. Similarly, the 60 first adhesive layer may not be needed. For example if the support layer includes an adhesive material, or if the film layer itself is formed from a hot melt adhesive then the film layer and the support layer may be directly adhered together.

In another example, the wound dressing may be provided 65 without the foam layer. The foam layer helps to transport exudate away from the wound. However in some cases, and

8

depending on the severity of a wound, the absorbent layer may sufficiently draw exudate from the wound without the need for the foam layer.

Although in the examples described above, the support layer is heat laminated to the absorbent layer via a bonding layer, other laminating techniques may be suitable. For example, the bonding layer may include a pressure sensitive adhesive. In this case, heat may not be required to laminate the support layer and adhesive layer together.

Although in the example described above, the net layer has been described as having a substantially hexagonal shaped structure, other geometric structures may also be suitable.

With other geometric structures, the apertures may also have different geometric shapes.

In another example, the wound dressing may include more than one support layer to provide support to other layers in the wound dressing. For example a first support layer may be located between the liquid impermeable film layer and the absorbent layer, and a further support layer may be located between the absorbent layer and the fluid transport layer (foam layer). This may help to support the absorbent layer from both sides to further reduce shrinking of the absorbent layer.

Any of the examples described herein may be adapted for use with a negative pressure system (sometimes referred to as a reduced pressure system) including a source of negative pressure, such as a negative pressure pump. For example, the film layer may include a negative pressure interface, such as a port, to which a negative pressure supply tube may be connected. The supply tube may be connected to a negative pressure source so that, in use, the negative pressure source applies a negative pressure to the wound dressing between the film layer and the wound to help draw wound exudate away from the wound and into the absorbent layer of the dressing.

FIG. 7 illustrates an example of a negative pressure wound therapy system 700. The system includes a wound cavity 710 covered by a wound dressing 720, which can be 40 a dressing according to any of the examples described herein. The dressing 720 can be positioned inside the wound cavity 710 and further seal the wound cavity so that negative pressure can be maintained in the wound cavity. For example, a film layer of the wound dressing 720 can provide substantially fluid impermeable seal over the wound cavity 710. A single or multi lumen tube or conduit 740 connects the wound dressing 720 with a negative pressure device 750 configured to supply reduced pressure. The negative pressure device **750** includes a negative pressure source. The 50 negative pressure device 750 can be a canisterless device (meaning that exudate is collected in the wound dressing and/or is transferred via the tube 740 for collection to another location). In some embodiments, the negative pressure device 750 can be configured to include or support a canister. Additionally, in any of the embodiments disclosed herein, the negative pressure device 750 can be fully or partially embedded in, mounted to, or supported by the wound dressing 720.

The conduit **740** can be any suitable article configured to provide at least a substantially sealed fluid flow path or pathway between the negative pressure device **750** and the wound cavity **710** so as to supply reduced pressure to the wound cavity. The conduit **740** can be formed from polyurethane, PVC, nylon, polyethylene, silicone, or any other suitable rigid or flexible material. In some embodiments, the wound dressing **720** can have a port configured to receive an end of the conduit **740**. For example, a port can include a

hole in the film layer. In some embodiments, the conduit 740 can otherwise pass through and/or under a film layer of the wound dressing 720 to supply reduced pressure to the wound cavity 710 so as to maintain a desired level of reduced pressure in the wound cavity. In some embodition ments, at least a part of the conduit 740 is integral with or attached to the wound dressing 720.

In use, the wound dressing, such as the wound dressing 100, 300, 500, or 600, is applied to a wound site with the wound contact layer 320 contacting the wound. Exudate 10 from the wound may pass through the perforated film 116 and into the foam layer 312, which acts to transport wound exudate away from the wound into the absorbent layer 308. Wound exudate collected in the absorbent layer 308 can evaporate from the wound dressing 300 through the vapour 15 permeable film layer 302.

The support layer helps to provide mechanical strength to the absorbent layer, which may swell when it is wet and may shrink as it dries. The support layer can help to minimise movement of fibres in the absorbent layer at least on the side 20 distal from the wound and thus helps to prevent shrinking of the wound dressing, particularly in this region. Minimising shrinking of the wound dressing in this way can in turn can help to prevent wrinkling of the film layer. It also reduced the chance of the dressing rolling/folding up under second- 25 ary retention.

As the wound dressing becomes exposed to moisture (either from the wound or the surrounding atmosphere), it may swell or expand causing increased wrinkling of the film layer. Having the support layer adhered to the film layer can 30 help to provide support to the film layer and resist wrinkling of the film layer by providing additional mechanical strength to the film layer.

The above described wound dressings are less likely to exhibit shrinking whilst stored in sterile packaging than 35 previously known wound dressings. Thus, wrinkling of the film layer on the outside of the wound dressing can be prevented or reduced. A medical practitioner is therefore less likely to disregard a wound dressing that is still within its recommended shelf life, sterile and suitable for use, purely 40 because of visual appearance of the film layer.

The hexagonal and/or triangular shape of the net structure of the support layer helps to provide mechanical strength and can be particularly effective at resisting against shrinkage of surrounding wound dressing layers.

Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of them mean "including but not limited to", and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description 50 and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. 60 All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel

10

one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

The invention claimed is:

- 1. A multi-layered wound dressing comprising:
- a fibrous absorbent layer for absorbing exudate from a wound site;
- a support layer configured to reduce shrinkage of at least a portion of the multi-layered wound dressing; and
- a liquid impermeable film layer,
- wherein the support layer is located between the absorbent layer and the film layer, and
- wherein the support layer has a tensile strength from 0.05 to 0.06 Nm.
- 2. A multi-layered wound dressing according to claim 1, wherein the support layer comprises a net.
- 3. A multi-layered wound dressing according to claim 2, wherein the net comprises a geometric structure having a plurality of substantially geometric apertures extending therethrough.
- 4. A multi-layered wound dressing according to claim 3, wherein the geometric structure comprises a plurality of bosses substantially evenly spaced and joined by polymer strands to form the plurality of substantially geometric apertures between the polymer strands.
- 5. A multi-layered wound dressing according to claim 4, wherein the geometric structure of the net comprises a hexagonal structure, and wherein the plurality of substantially geometric apertures have triangular shape.
- 6. A multi-layered wound dressing according to claim 5, wherein a boss of the plurality of bosses form a vertex of the hexagonal structure with polymer strands extending from the boss and connecting the boss to neighboring bosses, and wherein the plurality of substantially geometric apertures are formed between neighboring polymer strands.
- 7. A multi-layered wound dressing according to claim 2, wherein the net is formed from high density polyethylene.
- 8. A multi-layered wound dressing according to claim 3, wherein the plurality of substantially geometric apertures have an area from 0.005 to 0.32 mm².
- 9. A multi-layered wound dressing according to claim 1, wherein the support layer has a thickness of from 50 to 150 μm .
- 10. A multi-layered wound dressing according to claim 1, wherein the support layer is located directly adjacent the absorbent layer.
 - 11. A multi-layered wound dressing according to claim 1, wherein the support layer is bonded to fibres in a top surface of the absorbent layer.
 - 12. A multi-layered wound dressing according to claim 11, wherein the support layer further comprises a bonding layer, wherein the support layer is heat laminated to the fibres in the absorbent layer via the bonding layer.
 - 13. A multi-layered wound dressing according to claim 12, wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive, and wherein the support layer comprises a net formed from a material with a higher melting temperature than that of the bonding layer.

- 14. A multi-layered wound dressing according to claim 1, further comprising an adhesive layer attaching the film layer to the support layer.
- 15. A multi-layered wound dressing according to claim 1, further comprising a wound contact layer located adjacent 5 the absorbent layer for positioning adjacent a wound.
- 16. A multi-layered wound dressing according claim 15, further comprising a fluid transport layer between the wound contact layer and the absorbent layer for transporting exudate away from a wound into the absorbent layer.
- 17. A method of treating a wound comprising placing a multi-layered wound dressing according to claim 1 over a wound.
- 18. A method of manufacturing a multi-layered wound dressing, the method comprising:
 - forming a support layer that comprises a net layer and a bonding layer by coextruding the net layer and the bonding layer;

forming a fibrous absorbent layer for absorbing exudate from a wound site; and

laminating the support layer and the absorbent layer together to form the wound dressing by attaching the bonding layer to the absorbent layer;

12

wherein the support layer is configured to reduce shrinkage of at least a portion of the multi-layered wound dressing, and

wherein the support layer has a tensile strength from 0.05 to 0.06 Nm.

- 19. A method according to claim 18, wherein the bonding layer is formed from a polymer with a first melting temperature and the net layer is formed from a material with a second melting temperature higher than the first melting temperature of the polymer of the bonding layer, and wherein laminating the support layer and the absorbent layer comprises laminating by using heat so that the net layer maintains its structure during application of heat.
- 20. A method according to claim 18, further comprising heat laminating the support layer to fibres in the absorbent layer via the bonding layer, wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive, and wherein the support layer comprises a net formed from a material with a higher melting temperature than that of the bonding layer.

* * * *

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 11,559,437 B2

ADDITION NO. : 16/245106

APPLICATION NO. : 16/345196

DATED : January 24, 2023

INVENTOR(S) : Daniel Lee Steward

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification

Column 3, Line 41, below "In the drawings like reference numerals refer to like parts." insert -- DETAILED DESCRIPTION --, as a new heading.

Column 8, Line 14-15, delete "With other geometric structures, the apertures may also have different geometric shapes." and insert the same on Column 8, Line 13 as a continuation of the same paragraph.

In the Claims

Column 11, Line 7, in Claim 16, after "according" insert -- to --.

Signed and Sealed this Fourth Day of April, 2023

Lahreine Laire Value Vidal

Katherine Kelly Vidal

Director of the United States Patent and Trademark Office